BCRX BioCryst Pharmaceuticals, Inc.

5.92
-0.03  -0.5%
Previous Close 5.95
Open 5.91
Price To book 110.19
Market Cap 436.65M
Shares 73,758,000
Volume 637,109
Short Ratio 8.02
Av. Daily Volume 963,771

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Approved Dec 22 2014
Peramivir - Study 303
INFLUENZA ACUTE
Phase 2 data from Part 1 portion of trial due 1Q 2017.
BCX7353 - APeX-1
Reduce or eliminate attacks in HAE patients

Latest News

  1. BioCryst Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BCRX) : January 23, 2017
  2. ETFs with exposure to BioCryst Pharmaceuticals, Inc. : January 20, 2017
  3. BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : January 20, 2017
  4. BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  5. BioCryst Receives Health Canada Approval for RAPIVAB® for the Treatment of Influenza
  6. BioCryst to Present at the J.P. Morgan Healthcare Conference
  7. Can The Uptrend Continue for BioCryst Pharmaceuticals (BCRX)?
  8. Are Options Traders Betting on a Big Move in BioCryst (BCRX) Stock?
  9. A Trump Presidency May Be Good for Biotech
  10. ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 16, 2016
  11. ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 5, 2016
  12. What Smart Money Thinks about BioCryst Pharmaceuticals, Inc. (BCRX)?
  13. ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 23, 2016
  14. BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
  15. BioCryst to Present at the Piper Jaffray Healthcare Conference November 30
  16. BIOCRYST PHARMACEUTICALS INC Financials
  17. How investors are playing Biocryst
  18. ETF’s with exposure to BioCryst Pharmaceuticals, Inc. : November 9, 2016
  19. BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
  20. BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : November 8, 2016

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536859
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 17517498
  3. 8-K - Current report 17515655
  4. CT ORDER - Confidential treatment order 162071277
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161980859
  6. 8-K - Current report 161976601
  7. 8-K - Current report 161952446
  8. 8-K - Current report 161901182
  9. CT ORDER - Confidential treatment order 161884490
  10. 8-K - Current report 161873095